TG Therapeutics shares are trading higher after a Form4 filing showed CEO and President Michael Weiss bought 100,000 shares of stock at an average price of $10.13 per share.
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics' CEO and President, Michael Weiss, has purchased 100,000 shares of the company's stock at an average price of $10.13 per share. This has led to an increase in the company's stock price.
August 14, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The CEO's purchase of 100,000 shares has led to an increase in TG Therapeutics' stock price.
Insider trading, especially by high-ranking officials like the CEO, often signals confidence in the company's future prospects. This can lead to increased investor confidence and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100